Ontario Pharmacists and Avricore Health Partner to Expand HealthTab(TM) in Community Pharmacies and Enhance Patient Care
VANCOUVER, British Columbia, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) and the Ontario Pharmacists Association (OPA) are pleased to announce a Memorandum of Understanding (MOU) to offer in partnership the Company’s HealthTab™ point-of-care blood screening system to OPA member pharmacies.
According to the Government of Canada, nearly one percent of Canadians of six years of age and older, are undiagnosed diabetics. They also found women are more likely to die of heart disease, as their symptoms are more subtle and often go ignored until it’s too late.
Avricore’s revolutionary HealthTab™ point-of-care blood screening platform is ideal for screening consumers for the early signs of diabetes, heart attack and stroke risk, as well as liver and kidney function concerns.
By offering HealthTab™, a pharmacist is able to modernize their practice through advancements in point-of-care testing, as well as address the high consumer demand for easier access to health data evidence-based care.
“From the very beginning, the vision for HealthTab™ was to empower patients and healthcare teams with better data, for better health outcomes,” said Avricore’s President, Bob Rai. “To work with the largest Canadian professional association for pharmacists to expand the network, demonstrates this vision coming to life.”
There are over 4400 pharmacies in Ontario and the OPA is Canada's largest advocacy, professional development and drug information provider for pharmacy professionals across Ontario with more than 10,000 members.
With easier access to regular screening, patients and their healthcare teams, including their trusted pharmacist, can take action to improve health outcomes and lower the risk of serious illness.
“Our objective is to advance the pharmacy profession as a vital healthcare provider through advocacy, innovation and support services,” said OPA CEO, Justin Bates. “By offering technologies that enhance our pharmacists’ ability to serve patients, we are supporting an important step forward in our profession.”
Both parties look forward to quickly concluding the final agreement and launching this initiative within the next two weeks, which will mean expanding consumers access to their health data and supporting the pharmacy profession in delivering evidence-based care.
Under this first stage agreement, OPA agrees to facilitate introductions and subsequent discussions with relevant decision makers within the OPA membership and its affiliates, providing Avricore with opportunities for pharmacy exposure. OPA will also promote Avricore’s point-of-care technology and real-world evaluation offerings to pharmacies to expand the network.
Avricore agrees to provide remuneration to OPA on contracts generated through commercial agreements facilitated by OPA and will support OPA with research and insights by using data generated from participating members for the purposes of enhancing pharmacy practice, better addressing patient needs, identifying trends, and supporting consumer health advocacy.